GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma

Histopathology

Volumn 49, Issue 1, 2006, Pages 75-81

  Idrees, M T ^a   Schlosshauer, P ^a   Li, G ^a   Burstein, D E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinogenesis; Endometrial intraepithelial carcinoma; GLUT1; p63; Uterine serous papillary carcinoma

Indexed keywords

GLUCOSE TRANSPORTER 1; PROTEIN P53; PROTEIN P63;

ARTICLE; CANCER INVASION; CARCINOMA IN SITU; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROMORPHOLOGY; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS CARCINOMA;

CARCINOMA IN SITU; CYSTADENOCARCINOMA, PAPILLARY; ENDOMETRIAL NEOPLASMS; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 33745667491     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02447.x     Document Type: Article

References (38)

1. Chen LM, McGonigle KF, Berek JS. Endometrial cancer: recent developments in evaluation and treatment. Oncology 1999; 13; 1665-1670.
2. Deligdisch L, Holinka CF. Endometrial carcinoma: two diseases? Cancer Detect. Prev. 1987; 10; 237-246.
3. Ronnett BM, Zaino RJ, Ellenson LH, Kurman JR. In Kurman RJ ed. Blaustein's pathology of female genital tract, 5th edn. Berlin: Springer Verlag; 2002; 501-559.
4. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 2003; 53; 5-26.
5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983; 1; 10-17.
6. Kato DT, Ferry JA, Goodman A, Sullinger J. Uterine papillary serous carcinoma (UPSC): a clinicopathologic study of 30 cases. Gynecol. Oncol. 1995; 59; 384-389.
7. Jeffrey JF, Krepart GV, Lotocki RJ. Papillary serous adenocarcinoma of the endometrium. Obstet. Gynecol. 1986; 67; 670-674.
8. Spiegel GW. Endometrial carcinoma in situ in postmenopausal women. Am. J. Surg. Pathol. 1995; 19; 417-432.
9. Ronnett BM, Kurman JR. In Kurman RJ ed. Blaustein's pathology of female genital tract, 5th edn. Berlin: Springer Verlag; 2002; 493-497.
10. Hui P, Kelly M, O'Malley DM, Tavassoli F, Schwartz PE. Minimal uterine serous carcinoma: a clinicopathological study of 40 cases. Mod. Pathol. 2005; 18; 75-82.
11. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am. J. Surg. Pathol. 1998; 22; 1463-1473.
12. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000; 88; 14-24.
13. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 1997; 150; 177-178.
14. Darvishian F, Hummer AJ, Thaler HT et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am. J. Surg. Pathol. 2004; 28; 1568-1578.
15. Yang A, Kaghad M, Wang Y et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 1998; 2; 305-316.
16. Wang BY, Kalir T, Sabo E, Sherman DE, Cohen C, Burstein DE. Immunohistochemical staining of GLUT1 in benign, hyperplastic and malignant endometrial epithelia. Cancer 2000; 88; 2774-2781.
17. Santin AD, Bellone S, Gokden M et al. Overexpression of HER-2/Neu in uterine serous papillary cancer. Clin. Cancer Res. 2002; 8; 1271-1279.
18. Santin AD. HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol. Oncol. 2003; 88; 263-265.
19. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol. Res. 2002; 35; 9-26.
20. Merrall NW, Plevin R, Gould GW. Growth factors, mitogens, oncogenes and the regulation of glucose transport. Cell Signal. 1995; 5; 667-675.
21. Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 1996; 56; 1164-1167.
22. Younes M, Ertan A, Lechago LV, Somoana J, Lechago J. Human erythryocyte glucose transporter (Glut1) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia. Cancer Epidemiol. Biomarkers Prey. 1997; 6; 303-305.
23. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 1995; 15; 2895-2898.
24. Kalir T, Wang BY, Goldfischer M et al. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer 2002; 94; 1078-1082.
25. Behrooz A, Ismail-Beigi F. Stimulation of glucose transport by hypoxia: signals and mechanisms. News Physiol. Sci. 1999; 14; 105-110.
26. Osthus RC, Shim H, Kim S. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 2000; 275; 21797-21800.
27. Russo VC, Kobayashi K, Najdovska S, Baker NL, Werther GA. Neuronal protection from glucose deprivation via modulation of glucose transport and inhibition of apoptosis: a role for the insulin-like growth factor system. Brain Res. 2004; 1009; 40-53.
28. McGowan KM, Police S, Winslow JB, Pekala PH. Tumor necrosis factor-alpha regulation of glucose transporter (GLUT1) mRNA turnover. Contribution of the 3V-untranslated region of the GLUT1 message,. J. Biol. Chem. 1997; 272; 1331-1337.
29. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9 (Suppl. 5); 10-17.
30. Airley R, Loncaster J, Davidson S et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin. Cancer Res. 2001; 7; 928-934.
31. Oliver RJ, Woodwards RT, Sloan P, Thakker NS, Stratford IJ, Airley RE. Prognostic value of facilitative glucose transporter Glut-1 in oral squamous cell carcinomas treated by surgical resection: results of EORTC Translational Research Fund studies. Eur. J. Cancer 2004; 40; 503-507.
32. Mineta H, Miura K, Takebayashi S et al. Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. Anticancer Res. 2002; 22; 3489.
33. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev. 2001; 11; 293-299.
34. Yang A, Schweitzer R, Sun D et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398; 714-718.
35. Hendrickson MR, Kempson RL. Surgical pathology of the uterine corpus. Major Problems Pathol. 1979; 12; 1-580.
36. O'Connell JT, Mutter GL, Cviko A et al. Identification of a basal/reserve cell immunophenotype in benign and neoplastic endometrium: a study with the p53 homologue p63. Gynecol. Oncol. 2001; 80; 30-36.
37. Quade BJ, Yang A, Wang Y-M et al. Expression of the p5 3 homologue p63 in early cervical neoplasia. Gynecol. Oncol. 2001; 80; 24-29.
38. Di Como CJ, Urist MJ, Babayan I et al. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 2002; 8; 494-501.